The newly upgraded HKEY-AIDMD 3.0 model library contains nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established a four-dimensional (4D) model pool that simulates clinical heterogeneity, providing a mechanism-driven model selection platform for evaluating multi-target combination therapies.

The HKEY-AIDMD 3.0 omics database integrates spatiotemporal single-cell and spatial omics from a model library across various tissues and immune systems. This significantly improves the resolution to identify the differential benefits of multi-target combinations, revealing subtle differences between genes, molecules, cells, tissues and clinical phenotypes.

BOSTON and SUZHOU, China , Nov. 24, 2025 /PRNewswire/ -- HKeyBio, the world's leading CRO focused on preclinical and translational research for drug development in autoimmune and allergic diseases, has officially launched the upgraded HKEY-AIDMD 3.0 platform. The platform includes: (1) a four-dimensional model library of nearly 300 autoimmune and allergic disease models, and (2) a comprehensive spatiotemporal single cell and spatial omics database derived from these models. The platform is designed to significantly improve the predictive accuracy of clinical translation of multi-target combination therapies.

Autoimmune and allergic diseases result from dysregulation of immune networks in three major immune domains: multiple cellular components, multiple cytokine networks, and interconnected signaling pathways. These disorders involve abnormal activity of immune cell populations such as T cells, B cells, dendritic cells, and granulocytes; dysregulated cytokines, including IL-6, IL-4, and TNF; and perturbations of signaling pathways such as JAK/STAT, NF-κB, and BTK, as well as immune tolerance mechanisms. Since single-target drugs may have limited efficacy in certain patient populations, multi-target combinations may more comprehensively modulate pathological networks and improve treatment outcomes. In addition, due to the heterogeneity of the disease, multi-target therapy can more accurately match patient-specific pathogenic characteristics, supporting personalized treatment strategies.

However, multi-target drug development faces significant technical and clinical challenges. Due to the diversity of targets, dosing regimens, and mechanisms of action, the number of possible combinations increases exponentially. Given limited resources, prioritizing the most effective and safest combinations is an urgent unmet need. Achieving optimal combinations requires accurate mapping of key pathogenic nodes within disease networks and identification of predictive biomarkers of treatment response.

HKeyBio's newly upgraded HKEY-AIDMD 3.0 provides a practical solution to the 'optimal multi-target combination' challenge . Based on deep mechanistic insights into autoimmune and allergic diseases, HKeyBio has developed a pool of four-dimensional models across multiple species, strains, and induction strategies to simulate various disease subtypes and endotypes. These model pools enable the evaluation of in vivo interactions, feedback mechanisms, and synergistic effects of multi-target combinations. HKeyBio utilizes systems biology methods, including gene regulatory networks, protein-protein interaction networks, and pathway topology analysis, to identify key nodes and bottleneck targets in disease networks. Machine learning methods further support predictive modeling of combinatorial outcomes and discovery/validation of biomarkers such as gene signatures, single-cell immune profiles, and cytokine panels.

The HKEY-AIDMD 3.0 platform not only enhances the predictive value of multi-target efficacy, but also significantly improves developability and commercial cooperation value. By combining a pool of multi-indication 4D models with spatiotemporal omics, the platform provides critical support for new drug development in rheumatology, immunology and allergy. It improves mechanistic accuracy, provides high-resolution multidimensional biomarker discovery, and improves the reliability of predicting treatment response across multiple pathways.

About HKeyBio HKEY-AIDMD 3.0 Platform

The HKEY-AIDMD 3.0 model library covers nearly 300 autoimmune and allergy-related disease models. For the main indications, HKeyBio has built a 4D model pool that simulates clinical heterogeneity and supports mechanism-based model selection for multi-target combination evaluation. These include dermatology models (atopic dermatitis, urticaria, pruritus, hidradenitis suppurativa, psoriasis), respiratory system models (asthma, chronic obstructive pulmonary disease, pulmonary fibrosis), gastrointestinal tract models (inflammatory bowel disease, Crohn's disease), and rheumatic disease models (systemic lupus erythematosus, cutaneous lupus, Sjogren's syndrome, rheumatoid arthritis, systemic sclerosis, multiple sclerosis), etc.

The HKEY-AIDMD 3.0 omics database contains spatiotemporal single-cell and spatial omics across tissues and immune compartments for all models. The platform uses systems biology methods (including gene expression network, protein-protein interaction network and signal topology analysis) combined with machine learning to predict the effects of multi-target drug combinations and verify the effectiveness and safety of biomarkers, thereby significantly improving the resolution of distinguishing target combination strategies.

HKeyBio is an industry-leading CRO specializing in pharmacology and translational research for autoimmune diseases, with focus, focus, and extensive experience in autoimmune innovation.
For more information, please visit www.hkeybio.com

If you have any questions, please contact: us. bd@hkeybio.com

SourceHKeyBio